近日，一家在中国成立五年、专注罕见病领域的企业锐康迪（北京）医药有限公司（以下简称“锐康迪”）突然宣布，公司已经完成清算组备案，进入清算程序，全部业务活动将于近期全面中止，未来将无法继续提供任何形式的产品、服务或业务支持。该公司旗下目前有三款罕见病产品获批上市，其中两款已实现商业化上市。“随着锐康迪全面退出中国市场，旗下产品也将退出中国，对中国的罕见病患者影响还是很大的。我个人认为，锐康迪全面清算...
Source Link近日，一家在中国成立五年、专注罕见病领域的企业锐康迪（北京）医药有限公司（以下简称“锐康迪”）突然宣布，公司已经完成清算组备案，进入清算程序，全部业务活动将于近期全面中止，未来将无法继续提供任何形式的产品、服务或业务支持。该公司旗下目前有三款罕见病产品获批上市，其中两款已实现商业化上市。“随着锐康迪全面退出中国市场，旗下产品也将退出中国，对中国的罕见病患者影响还是很大的。我个人认为，锐康迪全面清算...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.